Hellow guys, Welcome to my website, and you are watching ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro. and this vIdeo is uploaded by European Society for Medical Oncology (ESMO) at 2023-06-19T06:47:02-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro |
| Video Uploader | Video From European Society for Medical Oncology (ESMO) |
| Upload Date | This Video Uploaded At 19-06-2023 09:47:02 |
| Video Discription | Reporting from ASCO 2023 Annual Meeting, Alessandra Curioni-Fontecedro summarises the results from three important studies in advanced NSCLC. In the CHRYSALIS 2 study, predictive biomarkers were identified to target the specific population that achieved a remarkable 61% response rate with the combination of amivantamab and lazertinib. The CodeBreaK 200 study investigators conducted a biomarker subgroup analysis identifying KRAS G12C-mutated NSCLC subgroup with co-alterations where sotorasib did not outperform docetaxel. The third study addressed the issue of neoadjuvant osimertinib non-responders in an EGFR-mutated NSCLC population, highlighting the need for further exploration of heterogeneity and other genetic alterations. Abstracts discussed: - Abstract 9013: Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS. - Abstract 8508: Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer. - Abstract 9008: Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Produced by the European Society for Medical Oncology http://oncologypro.esmo.org |
| Category | Science & Technology |
| Tags | ESMO | OncologyPRO | Alessandra Curioni-Fontecedro | CHRYSALIS 2 study | advanced NSCLC | Non-Small Cell Lung Cancer | CodeBreaK 200 study | predictive biomarkers | amivantamab | lazertinib | KRAS G12C-mutated | KRAS | sotorasib | docetaxel | neoadjuvant osimertinib | EGFR | Oncogene Driven |
